Test efficacy of anti-fibrotic drugs and explore mechanisms of fibrosis induction
The InSphero 3D InSight™ Human Liver Fibrosis Model is a primary human liver microtissue for in vitro screening of anti-fibrotic drug efficacy, and for studying mechanisms of fibrosis induction. It is engineered to incorporate all relevant human liver cells needed to recapitulate the fibrotic disease state, including hepatocytes, Kupffer cells, hepatic stellate cells, and liver endothelial cells. Liver fibrosis is inducible in the model by treatment with TGF-β1. This powerful liver disease model has been rigorously characterized under basal and induced fibrotic conditions using histological techniques (IHC and IF), gene-expression analysis (qPCR) and secreted biomarker (ELISA) analysis.
The 3D InSight™ Human Liver Fibrosis Model enables the study of liver fibrosis induction and inhibition of disease progression. The screening-compatible 3D microtissue format provides maximal endpoint compatibility.
InSphero 3D InSight™ Human Liver Fibrosis Models are produced and shipped to customers in the United States and Europe. For pricing information, availability, and shipping costs, click on the Get Started button at the bottom of this page.
|MT-02-302-05||3D InSight™ Human Liver Fibrosis Model (96x)|
|CS-07-001-01*||Maintenance Medium – TOX, 500 mL|
* only available when purchased with 3D InSight™ Microtissues